329 related articles for article (PubMed ID: 16960105)
41. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Virani SS; Nambi V
Curr Atheroscler Rep; 2007 Aug; 9(2):97-103. PubMed ID: 17877917
[TBL] [Abstract][Full Text] [Related]
42. [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Bonnefont-Rousselot D
Ann Pharm Fr; 2016 May; 74(3):190-7. PubMed ID: 26499399
[TBL] [Abstract][Full Text] [Related]
43. Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Li Y
Technol Health Care; 2015; 23 Suppl 1():S147-50. PubMed ID: 26410317
[TBL] [Abstract][Full Text] [Related]
44. [The correlation of human serum Lp-PLA2 and hs-CRP and stability of coronary atherosclerotic plaques].
Xu DL; Liu JN; Du YM; Yao GH; Jiang WD; Wang X; Dong ZQ; Hao L; Wang GY; Sui SJ; Li JF; Lu QH
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):651-4. PubMed ID: 19954057
[TBL] [Abstract][Full Text] [Related]
45. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
[TBL] [Abstract][Full Text] [Related]
46. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
47. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death.
Kolodgie FD; Narula J; Burke AP; Haider N; Farb A; Hui-Liang Y; Smialek J; Virmani R
Am J Pathol; 2000 Oct; 157(4):1259-68. PubMed ID: 11021830
[TBL] [Abstract][Full Text] [Related]
48. Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia.
Korkmaz L; Erkuş E; Kırış A; Ağaç MT; Acar Z; Turan T; Erkan H; Dursun I; Celik S
Clin Res Cardiol; 2011 Jun; 100(6):511-4. PubMed ID: 21207044
[TBL] [Abstract][Full Text] [Related]
49. The natural history of aortic atherosclerosis: a systematic histopathological evaluation of the peri-renal region.
van Dijk RA; Virmani R; von der Thüsen JH; Schaapherder AF; Lindeman JH
Atherosclerosis; 2010 May; 210(1):100-6. PubMed ID: 20031134
[TBL] [Abstract][Full Text] [Related]
50. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
51. Lp-PLA2: a new kid on the block.
Zalewski A; Nelson JJ; Hegg L; Macphee C
Clin Chem; 2006 Sep; 52(9):1645-50. PubMed ID: 16873290
[TBL] [Abstract][Full Text] [Related]
52. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.
Gajos G; Zalewski J; Mostowik M; Konduracka E; Nessler J; Undas A
Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):434-9. PubMed ID: 24555913
[TBL] [Abstract][Full Text] [Related]
53. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
54. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.
Khuseyinova N; Imhof A; Rothenbacher D; Trischler G; Kuelb S; Scharnagl H; Maerz W; Brenner H; Koenig W
Atherosclerosis; 2005 Sep; 182(1):181-8. PubMed ID: 16115490
[TBL] [Abstract][Full Text] [Related]
55. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques.
Tavora FR; Ripple M; Li L; Burke AP
BMC Cardiovasc Disord; 2009 Jun; 9():27. PubMed ID: 19549340
[TBL] [Abstract][Full Text] [Related]
56. Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis.
Liu J; Wang W; Qi Y; Yong Q; Zhou G; Wang M; Sun J; Liu J; Jia Z; Zhao D
J Atheroscler Thromb; 2014; 21(6):532-42. PubMed ID: 24492522
[TBL] [Abstract][Full Text] [Related]
57. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Corsetti JP; Rainwater DL; Moss AJ; Zareba W; Sparks CE
Clin Chem; 2006 Jul; 52(7):1331-8. PubMed ID: 16709622
[TBL] [Abstract][Full Text] [Related]
58. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque.
Sarlon-Bartoli G; Boudes A; Buffat C; Bartoli MA; Piercecchi-Marti MD; Sarlon E; Arnaud L; Bennis Y; Thevenin B; Squarcioni C; Nicoli F; Dignat-George F; Sabatier F; Magnan PE;
Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):154-9. PubMed ID: 22075154
[TBL] [Abstract][Full Text] [Related]
59. Lp-PLA2: an emerging biomarker of coronary heart disease.
Dada N; Kim NW; Wolfert RL
Expert Rev Mol Diagn; 2002 Jan; 2(1):17-22. PubMed ID: 11963798
[TBL] [Abstract][Full Text] [Related]
60. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.
Kardys I; Oei HH; van der Meer IM; Hofman A; Breteler MM; Witteman JC
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):631-6. PubMed ID: 16373603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
